Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:Richard_Saynor
|
| gptkbp:country |
gptkb:Switzerland
|
| gptkbp:founded |
2023
|
| gptkbp:headquartersLocation |
gptkb:Basel,_Switzerland
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:name |
gptkb:Sandoz
|
| gptkbp:notableEvent |
spinoff from Novartis completed in October 2023
|
| gptkbp:numberOfEmployees |
~22,000
|
| gptkbp:origin |
spun off from Novartis
|
| gptkbp:parentCompany |
formerly Novartis
|
| gptkbp:products |
biosimilars
generic pharmaceuticals |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:SIX_Swiss_Exchange
|
| gptkbp:stockSymbol |
gptkb:SDZ
|
| gptkbp:website |
https://www.sandoz.com/
|
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sandoz (2023)
|